To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts, namely ML017, ML015 and ML004 differing for the break point of the fusion gene FUS-CHOP, respectively of type I, II and III. FUS-CHOP binding to the promoters of some target genes such as Pentraxin 3 or Fibronectin 1, assessed by chromatin immunoprecipitation, was strongly reduced in the tumor 24 h after the first or the third weekly dose of trabectedin, indicating that the drug at therapeutic doses causes a detachment of the FUS-CHOP chimera from its target promoters as previously shown in vitro. Moreover, the higher sensitivity of MRCL types I and II appears to be related to a more prolonged block of the transactivating activity of the fusion protein. Doxorubicin did not affect the binding of FUS-CHOP to target promoters. Histologically, the response to trabectedin in ML017 and ML015 was associated with a marked depletion of non-lipogenic tumoral cells and vascular component, as well as lipidic maturation as confirmed by PPARg2 expression in western Blot. By contrast, in ML004 no major changes either in the cellularity or in the amount of mature were found, and consistently PPARg2 was null. In conclusion, the data support the view that the selective mechanism of action of trabectedin in MRCL is specific and related to its ability to cause a functional inactivation of the oncogenic chimera with consequent derepression of the adypocytic differentiation.
INTRODUCTION
Myxoid liposarcoma is a specific histological type within the family of adult soft tissue sarcomas. 1 It accounts for one-third of liposarcomas and mostly arises in the deep soft tissues of the extremities of adult younger than other sarcomas histotypes.
Microscopically, myxoid liposarcoma is characterized by the presence of myxoid stroma, branching capillary pattern, round/ oval-shaped primitive non-lipogenic mesenchymal cells and a variable number of monovacuolated lipoblasts. Better defined by its synonym: myxoid/round cell liposarcoma (MRCL), this tumor represents a morphological continuum of a single biologic entity that differs in the fraction of round cell component. The usual myxoid variant (ML) shows low cellularity, conspicuous vascular network and myxoid stroma, whereas the round cell variant (RCL) shows high cellularity made up of closely packed roundish cells, little or no intervening stroma and a capillary pattern not easy to be visualized. Diagnosis of RCL requires the presence of a round cell component exceeding 5%. 2 This amount is of prognostic relevance as within the MRCL spectrum, the 5-year survival varies between 20 and 70%, and RCL falls in the shortest figures. Recently, the increase in aggressiveness of RCL has been correlated with the activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway 3 or via activating mutations of phosphoinositide 3-kinase (PI3K) 4 or inactivation of phosphatase and tensin homolog (PTEN). 3, 5 In line with the morphological continuum and the concept of single biological entity, the ML and RCL share the same balanced translocation, most commonly t(12;16)(q13;p11) fusing FUS (also named as TLS) with CHOP (also named as DDIT3) and rarely t(12;22)(q13;q12), where EWS (Ewing's Sarcoma protein) substitutes for its homologous FUS. The fusion FUS-CHOP-and EWS-CHOP-encoded proteins are believed to function as abnormal transcription factors. FUS-CHOP oncogene consists of the NH2-terminal domain of FUS fused to the entire coding sequence of CHOP. 6, 7 The NH2-terminal domain of FUS confers the transactivation domain to the fusion protein. 8, 9 CHOP is a member of the C/EBP family of transcription factors that contain a basic leucine zipper domain and a DNA-binding domain. 10, 11 CHOP takes part in many processes that involve a response to noxious stimuli, particularly the endoplasmic reticulum stress response. Its expression is tightly regulated and the protein is also implicated in developmental programs. 12, 13 One of the most important functions of CHOP is to heterodimerize with other members of the family, serving as a dominant-negative protein by altering their transcriptional potential. 12 Within the constitutively active FUS-CHOP or EWS-CHOP chimeras, CHOP retains the heterodimerization and DNA-binding domains affecting the normal C/EBP activities. whereas C/EBPa becomes active and important in the later phases leading to terminal differentiation together with PPARg 1, 2. 16 The relevance of the expression of the fusion protein FUS-CHOP/ EWS-CHOP in the pathogenesis of MRCL is well established. 17, 18 Remarkably, while the fusion oncoproteins have a role in tumor initiation, the tumor progression correlates with round cell transformation. 19 FUS-CHOP presents 12 transcript variants that differ for the structure of the FUS-CHOP fusion genes. The exons 2, 3 and 4 of the CHOP gene are present in all types of fusion proteins except for type IV that lacks the exon 2. The FUS component is much more variable in different groups. The type II contains exons from 1 to 5, the type I contains exons from 1 to 7 and the type III contains exons from 1 to 8. The majority of patients (70%) have the type II FUS-CHOP fusion gene, and a lower percentage of patients present with type I and III fusion genes, whereas the other types are extremely rare. [20] [21] [22] [23] Among the rare EWS-CHOP fusion proteins, the type I transcript, wherein EWS exon 7 (that corresponds to FUS exon 5) is fused to CHOP exon 2, is the most represented. 20, 24 Trabectedin (ET-743, Yondelis) is a marine alkaloid isolated from the tunicate Ecteinascidia turbinata, now produced synthetically, which is cytotoxic against a variety of tumor cell lines in vitro [25] [26] [27] [28] [29] and human tumor xenografts in vivo. 30, 31 It has been approved by European Medicines Agency's (EMA) for the second line therapy of soft tissue sarcomas in 2007 and for the second line therapy of ovarian cancer in 2009. It is a tetrahydroisoquinoline alkaloid composed by three fused rings that binds the N 2 position of guanine in the minor groove of DNA, inducing a DNA bending toward the major groove. 32 The mode of action of trabectedin has been recently reviewed in detail. 33 Trabectedin was shown to be less active in cells deficient in nucleotide excision repair, suggesting that part of its cytotoxicity can be mediated by the activation of nucleotide excision repair. 34, 35 Instead, cells deficient in homologous recombination repair are much more sensitive to trabectedin. 36 In addition, the drug causes a gene-and promoter-dependent modulation of transcription, [37] [38] [39] [40] [41] and seems to be selectively cytotoxic against macrophage, thus modifying the tumor microenvironment. 42, 43 Recent clinical evidence shows that trabectedin is particularly effective in myxoid liposarcoma, [44] [45] [46] and studies in an immortalized myxoid liposarcoma cell line indicate that the high sensitivity of this tumor might be related to the ability of the drug to act as a differentiating agent by blocking the transactivating ability of the fusion gene product. 47 Only a limited number of in vitro growing myxoid liposarcoma cell lines are available and they do not necessarily mimic the complex biological features of this tumor. For this reason, xenografts of myxoid liposarcoma that are apparently biologically very close to the human tumors were recently developed. 48 In a recent phase II clinical trial with trabectedin in advanced localized MRCL, it was reported that in all cases of tumor regression, there was a decrease of cellular components that paralleled the replacement with an acellular hyalinized stromal component. 49 These observations closely mirror the results obtained in xenografts of MRCL treated with trabectedin. 48 In a fully characterized series of 19 MRCL patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, all the 17 responders to the trabectedin treatment expressed the same translocation with a FUS-CHOP gene of type II, whereas the two patients who did not respond showed a FUS-CHOP fusion gene of type III. 44 Although the number of cases is not sufficient to draw definitive conclusions, these preliminary results suggest that trabectedin has a selective antitumor activity against MRCL with a FUS-CHOP fusion gene of type II.
The aim of this study was to elucidate the specific mechanism of action of trabectedin in MRCL using well-characterized MRCL xenografts expressing different FUS-CHOP variants that mimic the biology and the drug-sensitivity properties observed in the clinic.
RESULTS

Antitumor activity of trabectedin in xenograft models
The antitumor activity of trabectedin was evaluated in ML017 (type I fusion transcript), ML015 (type II fusion transcript) and ML004 (type III fusion transcript) mouse xenografts after intravenous (i.v.) administration of 0.15 mg/kg, every 7 days for three times (q7d Â 3). Treatments started when tumor burden reached B400-800 mg (late-stage tumors), giving us the possibility to observe both tumor growth and regression.
As shown in Figures 1a and d , ML017 and ML015 were very sensitive to the treatment (T/C 26% on day 108 and 17.4% on day 175, respectively): in these xenograft models trabectedin was able to induce partial tumor regression (up to 50% in ML015) followed by a long-lasting tumor growth arrest. On the contrary, trabectedin was only marginally active in ML004 xenograft being able to slightly reduce tumor growth rate but without reaching a significant value of T/C (52.2% on day 156) (Figure 1g ). Histological analysis revealed in all the three pretreated cases findings recapitulating RCL. Trabectedin caused in ML017 and ML015 marked depletion of non-lipogenic tumoral cells and vascular component as well as lipidic maturation (Figures 1b and e) . On the contrary, xenograft ML004 did not show changes either in the cellularity or in the amount of mature lipoblasts ( Figure 1h ). Interestingly, as observed in humans, post-trabectedin samples did not exhibit signs of apoptosis, that is, cytoplasm shrinkage, chromatin condensation and nuclear fragmentation. Coagulative necrosis is a rare event and does not seem ascribable to the drug activity being restricted to high cellular tumor that already harbor necrotic areas before the treatment in line with their aggressive behavior.
Trabectedin induces adipogenic differentiation in MRCL type I and type II but not in MRCL type III We examined the expression levels of the adipocyte marker, PPARg2, in xenografts before and after treatment. As shown in 
Trabectedin blocks FUS-CHOP binding in vivo
We used chromatin immunoprecipitation (ChIP) analysis to monitor the binding of the chimera to well-known target genes such as PTX3 and FN1.
47 ML017 with FUS-CHOP type I, ML015 with FUS-CHOP type II and ML004 with FUS-CHOP type III xenografts were treated with 0.15 mg/kg of trabectedin q7d Â 3. Samples were collected 24 h after the first dose and 24 h after the third dose. As there is no available antibody to recognize specifically the chimera, FUS-CHOP was precipitated by the anti-FUS and anti-CHOP antibodies separately to monitor both FUS and CHOP in the same ChIP. Trabectedin inhibition is more prolonged in tumors with FUS-CHOP type I and type II than with FUS-CHOP type III To further investigate the difference in response observed between the three different xenografts (Figure 1 ), we performed ChIP assay to see whether there was a difference in kinetics of rebinding of FUS-CHOP between MRCL type I, type II and type III. Xenografts were treated with 0.15 mg/kg of trabectedin q7d Â 3. Samples were collected 72 h and 7 days after the first dose and 72 h, 120 h and 7 days after the last dose of trabectedin. PTX3 and FN-1 promoters were evaluated in RT-PCR as fold enrichment over anti-flag antibody. ChIP analysis performed 72 h after the first and the third treatment in ML017 and ML015 xenografts revealed that FUS-CHOP type I and type II were still detached from PTX3 and FN-1 promoters (Figures 3a and b) , whereas in ML004 xenograft, FUS-CHOP type III was already rebound to its target genes (Figure 3c ). One hundred twenty hours after treatment, type II and type III chimeras were bound to the promoters similar to that in control tumors, whereas type I chimera was still detached. These results suggest that the greater sensitivity of type I and type II than that of type III myxoid liposarcoma xenografts could be related to a more prolonged drug-induced detachment of the FUS-CHOP chimera from its target genes.
Specificity of the mechanism of action of trabectedin In order to evaluate whether the displacement of the chimera could be the result of an unspecific DNA damage, we tested the effect of doxorubicin at an effective dose. Twenty-four hours after doxorubicin treatment, FUS-CHOP type I (Figure 4a ), type II ( Figure 4b ) and type III ( Figure 4c ) were bound to PTX3 and FN-1 promoters in tumors of both control and treated mice, confirming the specificity of the mechanism of action of trabectedin. Figure 5 showed the pathological and molecular responses obtained in ML017 xenograft carrying a type I FUS-CHOP chimera after standard treatment with doxorubicin (8 mg/kg q7d Â 2). This xenograft model was chosen because of the more prolonged displacement of FUS-CHOP type I from its target genes observed after trabectedin exposure. Doxorubicin caused tumoral cell depletion but at variance with trabectedin, its effect on vascular component is less impressive (Figure 5a ). As depicted by the figure, the amount in branching vessels was greater after doxorubicin than after trabectedin treatment, whereas the adipocytic maturation was not evident. Consistently, at molecular level, trabectedin (Figure 1c ) but not doxorubicin (Figure 5b ) induced the expression of PPARg2, indicating that only trabectedin was able to activate the adipogenic pathway in MRCL.
As it was previously reported that trabectedin can induce cell death by apoptotic mechanism and cell cycle perturbations, we have investigated if these pathways were affected by trabectedin treatment (Supplementary Text 1) . As reported in the Supplementary Information we did not find any significant and consistent changes in the expression of apoptotic, cell cycle Tables 1 and 2 ). However, pathway analysis revealed an inhibition of interferon signaling in ML015 but not in ML004 (Supplementary  Tables 3-8) .
Biopsies of metastatic lesions of MRCL We obtained tumor biopsies from a patient with a clinical diagnosis of MRCL, both before and after trabectedin treatment. When we received the samples, the molecular characterization of the tumors was ongoing. Thus, we processed all the available specimens using the antibodies against FUS and CHOP similar to that in the experiments conducted in xenograft biopsies. Only later we were informed that the tumor did not express the most frequent FUS-CHOP chimera, but the least frequent EWS-CHOP chimera, whose characterization revealed the presence of the type I transcript. 24 Figure 6 shows that after trabectedin, the enrichment of CHOP is clearly decreased. The decrease in CHOP enrichment indicates that trabectedin was able to remove the oncoprotein from DNA in clinical tumor biopsy taken 24 h after treatment with trabectedin at the dose of 1.1 mg/m 2 . Thus, the mechanism of displacement of the chimera observed in xenografts appeared to be confirmed in a MRCL patient characterized by a EWS-CHOP transcript type I, which is somewhat homologous to FUS-CHOP type II transcript. This patient has continued for 11 Trabectedin specificity in myxoid liposarcoma S Di Giandomenico et al cycles of infusions, resulting in a response both in size and density of the tissue already after three cycles of treatment.
DISCUSSION
The present study shows that trabectedin induces the displacement of FUS-CHOP chimera from the promoters of target genes in vivo in human MRCL growing in mice. This effect was observed giving tolerable therapeutic doses of trabectedin, suggesting that the highly selective antitumor activity of trabectedin associated with the drug's ability to induce adipocytic differentiation of MRCL is related to the ability of the drug to impair the transactivating function of the chimera. This mechanism is likely responsible also for the striking antitumor activity of trabectedin in patients with MRCL. 44, 45 Consistently, analyzing tumoral tissue obtained from biopsy in one patient who received a relative low dose of trabectedin of 1.1 mg/m 2 corresponding to B75% of the recommended dose, we found that the drug is able to displace the chimera from DNA. To our knowledge, this is the first report indicating that a small molecule can displace an oncogenic transcription factor in vivo from its target DNA sequences, thus specifically modulating the transcription of genes involved in the pathogenesis of a neoplastic disease. Many attempts previously made to identify compounds that selectively block oncogenic transcription factors have failed, although many in vitro data have been published using many different molecules including nucleic acids, peptides and also small DNA-binding ligands. [50] [51] [52] For example, some years ago, our group had reported that some Figure 3 . ChIP assay was performed on ML017 (a), ML015 (b) and ML004 (c) xenografts to evaluate the kinetic of rebinding of the three different FUS-CHOP sub-type to PTX3 and FN-1 promoters. Mice were treated with trabectedin 0.15 mg/kg q7d Â 3. Tumor samples were collected 72 h and 7 days after the first dose, and 72 and 120 h and 7 days after the third dose.
Trabectedin specificity in myxoid liposarcoma S Di Giandomenico et al natural products binding in the minor groove in AT-rich DNA sequences such as distamycins were able to specifically prevent the binding of some transcription factors to DNA 53 and similar data were published for other DNA minor groove binders. 54 However, these in vitro findings were never confirmed in vivo, thus justifying some skepticisms about the possibility to target transcription factors as a potential anticancer therapy, although it remained theoretically very appealing considering the large number of tumors that are driven by an altered function of transcription factors. The reason why this approach was not successful is related to the fact that, in vivo, the complexity of the transcription regulation is much higher than in vitro, involving interactions between multiprotein complexes and chromatin, and drug design is not feasible because the three-dimensional structures of the complexes is not fully elucidated yet. In this respect, the finding that trabectedin, a marine natural product that binds to the minor groove of DNA modifying DNA bending with some degree of sequence specificity, 32, 55 can specifically block the DNA binding of an oncogenic transcription factor in a specific manner is of great scientific interest and may stimulate the interest in setting up drug discovery programs aimed at identifying new compounds that are directed to the inhibition of transcription factors.
The high level of specificity of the observed mechanism of action of trabectedin in MRCL is highlighted by the observations that the drug-induced differentiation could be influenced by the break point of the translocations. We found that MRCL type I and type II xenografts were more sensitive to trabectedin than type III ones, these results being in keeping with higher probability of response in patients with type II than with type III chimera. 44 Previous studies have identified a number of transcription factors involved in adipocyte differentiation. These include PPARg and members of the C/EBP family of transcription factors. [56] [57] [58] These transcription factors are expressed as a cascade in which C/EBPb and C/EBPd, expressed during the first stages of the adipocyte differentiation program, induce the expression of C/EBPa and PPARg, the master regulators of adipogenesis. A positive feedback loop mechanism between PPARg and C/EBPa enhances their activities. 56, 58 There are two PPARg isoforms generated by alternative splicing, PPARg1 and PPARg2, with PPARg2 being more efficient to induce terminal differentiation in vitro. 16, 57 According to this, we analyze the expression level of PPARg1 and PPARg2. We found that after trabectedin, the expression of PPARg2 was induced in ML017 carrying FUS-CHOP type I and ML015 carrying FUS-CHOP type II (Figures 1c and f) but not in ML004 carrying FUS-CHOP type III (Figure 1i ). Taken together, these data provide evidence that trabectedin induces adipocytic differentiation in MRCL carrying type I and type II FUS-CHOP but not in MRCL expressing type III FUS-CHOP.
Although radiation and chemotherapy are also able to induce in MRCL-marked tumoral cellular depletion coupled with extensive stromal hyalinization, post-trabectedin changes show a more striking decrease (and eventually disappearance) of branching vascular supply and more frequent evidence of lipid maturation features. The decrease in the vascular component is in keeping with the known capacity of trabectedin to inhibit proinflammatory cytokines released by MRCL cells, 42, 43 and lipid maturation is in line with immunophenotypic profile observed in human specimens. 47 In this respect, it is interesting to note that gene expression analysis indicated an effect on interferon signaling pathway in the type II MRCL but not in the type III MRCL (Supplementary Tables 3-8 ). However, a non-arguable approach to evaluate maturation changes requires a comparison of pre-and posttreated thoroughly sampled surgical specimens in each patient because maturation is associated with MRCL make-up and may be present at various levels in naive tumors. 49, 59 Such an approach is precluded for patients who underwent preoperative treatments and whose diagnostic assessment is based on small biopsy or tru-cut. We overcame this restrain using xenografts that closely mirror morphological, molecular and biochemical characteristic of human MRCL, 48 and we demonstrated that the antitumor activity of trabectedin in type I and type II MRCL is associated with the induction of differentiation. The morphological findings were further confirmed by western blot assay showing induction of PPARg2, a biomarker of adipocytic differentiation, after trabectedin treatment. The effect appears specific for trabectedin as demonstrated by the fact that the antitumor effects of doxorubicin were not associated with the induction of PPARg2 expression. The striking anti-angiogenic effect observed with trabectedin and not with doxorubicin require further mechanistic studies, but it is tempting to speculate that the mechanism is related to the ability of trabectedin to inhibit the production of angiogenic factors by the MRCL cells. 42, 43 This hypothesis is supported by the evidence that FUS-CHOPtransfected cells produce a much greater amount of angiogenic factors including vascular endothelial growth factor (VEGF) and this production can be inhibited by trabectedin. 42 The different response to trabectedin observed in type I, type II and type III MRCL could be because of a different ability of the drug to displace the binding of the chimera from target promoters. The experiments done, however, showed that in all three molecular subtypes after trabectedin treatment FUS-CHOP was not bound to DNA. Nevertheless, when the treatment was stopped, the kinetics of reattachment of the chimera to DNA appeared different for the three molecular subtypes, being faster for the type III than for type II and type I. These differences might justify the different biological effects observed in the different subtypes. It might be speculated that the larger size of type III chimera makes the complex of transcription factor-cofactors and DNA more stable. Therefore, when the drug is partially cleared from the tumor some days after treatment, the drug concentrations in tumor cells might be sufficient to prevent the binding of type I and type II but not of type III chimera. Alternatively, for some reasons, the amount of drug bound to DNA of type I and type II remained longer than on type III, implying that some differences in the DNA repair mechanisms occur.
At any rate, these findings justify the idea that to obtain a better effect also in type III MRCL, the interval between doses should be reduced, and studies are in progress to test this hypothesis in preclinical MRCL xenograft models.
In summary, we have provided evidence that trabectedin has a highly specific mode of action in MRCL, being able to displace the product of the fusion gene that represents the hallmark and the pathogenetic lesion of the disease from its target promoters. The functional inactivation of the oncogenic chimera by trabectedin leads to the derepression of the adipocytic differentiation. The duration of the block of the transactivating activity of the chimera seems to be important as highlighted by the differences in type I, type II and type III MRCL, a finding of potential clinical importance to attempt different dosage schedules of the drug according to the molecular characterization of the fusion gene.
The studies shown in the present paper highlight the concept that transcription factors can be realistically targeted by small molecule and thus screening systems suitable for the identification of compounds able to specifically block oncogenic transcription factors should be developed.
MATERIALS AND METHODS Animals
Female athymic NCr-nu/nu mice, 7 weeks old, were obtained from Harlan Laboratories (Udine, Italy). They were housed in the Institute's animal care facilities under specific pathogen-free conditions, housed in individually ventilated cages and handled using aseptic procedures. 
In vivo studies
For the antitumor activity studies, mice were engrafted subcutaneously with ML017 (type I transcript), ML015 (type II transcript) or ML004 (type III transcript) tumor fragments as previously described. 48 All xenografts carried wild-type p53 as assessed by DNA sequencing of TP53 gene hot spots (exons 5, 6, 7 and 8). 60 Tumors were measured with a caliper, and their weights (1 mm 3 ¼ 1 mg) were calculated with the formula: length Â (width) 2 /2. When tumor weight reached B400 mg, mice were randomized and treatment was started. Trabectedin (generously provided by PharmaMar, Madrid, Spain) was given i.v. at the dose of 0.15 mg/kg, every 7 days for three times (q7d Â 3). Each group comprised at least seven mice.
Drug efficacy was calculated as T/C%, where T and C are the mean tumor weights of treated and control groups, respectively. Treatment was considered active when T/C o42%.
For the molecular analysis, mice bearing type I (ML017), type II (ML015) or type III (ML004) xenografts were treated with trabectedin, starting when the tumor weight reached B600 mg. Mice were killed at different time points after the first and the third dose of trabectedin. To verify the specificity of the mechanism of action of trabectedin, xenografts were treated with doxorubicin 8 mg/kg i.v. and killed 24 h after treatment. Tumors were immediately collected and snap-frozen on dry ice or processed for ChIP as described later. In order to minimize the effect of subjective bias in animal selection and outcome assessment, the allocation of each group of mice to the specific treatment was performed in a blinded manner, and all the molecular analyses since the sample collection were codified and analyzed by two different persons.
Hematoxylin/eosin staining was performed in ML017, ML0015 and ML004 xenografts before and 15 days after the third dose of trabectedin, and in ML017 15 days after the administration of doxorubicin 8 mg/kg every 7 days for two times (q7d Â 2).
Chromatin immunoprecipitation
Tumors were washed in phosphate-buffered saline and incubated for 10 min with 1% formaldehyde. After quenching the reaction with glycine 0.1 M, the cross-linked material was sonicated into chromatin fragments of an average length of 500/800 bp. Immunoprecipitations were performed with ProtG Sepharose (KPL, Milan, Italy) and 5 mg of the indicated antibodies: CHOP (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), FUS (Bethyl, Montgomery, TX, USA) and anti-Flag antibody (Sigma-Aldrich, Milan, Italy). The chromatin solution was precleared by adding ProtGSepharose for 2 h at 4 1C, and was aliquoted and incubated with the antibodies overnight at 4 1C on a rotating wheel. ProtG-Sepharose was blocked with 1 mg/l salmon sperm (Sigma-Aldrich) and 10 mg/l bovine serum albumin overnight at 4 1C and incubated with chromatin and antibody for 2 h. Immunoprecipitated material was washed nine times with wash buffer. Cross-links were reversed by incubating samples for 5 h at 65 1C in 200 mM NaCl and 10 mg of RNase A to eliminate RNA. Recovered material was treated with proteinase K, extracted with phenol/chloroform/ isoamyl alcohol (25:24:1) and precipitated. The immunoprecipitated DNAs were resuspended in 50 ml of water and analyzed by quantitative RT-PCR. Values are reported as fold enrichment over the control antibody-Flag.
Satellite sequences repeated at multiple positions in the genome were used as a control for unspecific precipitation and as a loading control. The RT-PCR primers used for detection of the proximal promoter sequences were: PTX3 forward 5 0 -CCCACCAAATTCAGGGGAACT-3 0 and reverse 5 0 -GCATTGCTGGAGAGACGCAAA-3 0 ; FN-1 forward 5 0 -CTTCGCTTCAC ACAAGTCCA-3 0 and reverse 5 0 -GCAGCGAACAAAAGAGATGC-3 0 . Control satellite sequences were amplified using forward 5 0 -CAATTATCCCTTCGGG GAATCGG-3 0 and reverse 5 0 -GGCGACCAATAGCCAAAAAAGTGAG-3 0 primers.
Western blot analysis
Whole-protein extracts were obtained by using a lysis buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Nonidet NP-40, 5 mM EDTA, 50 mM NaF in the presence of protease inhibitors (Roche, Basel, Switzerland). Proteins were quantified using the Bradford assay reagent (Bio-Rad Laboratories, Inc., Melville, NY, USA), separated on a SDS-PAGE gel, transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon, Millipore, Billerica, MA, USA) and probed with the primary: PPARg1,2, b-Actin (Santa Cruz Biotechnology). Binding was detected using peroxidase-labeled secondary antibodies and visualized using a chemiluminescence kit (Amersham, Milan, Italy).
Acquisition of tumor biopsies
The biopsy was obtained from a 43-year-old patient with recurrent MRCL in a lower extremity with metastasis to soft tissue, pleura, mediastinum and heart. The written informed consent was received from the patient before his inclusion in the study. The study protocol was approved by the Independent Local Ethics Committee of the Fondazione IRCCS-Istituto Nazionale dei Tumori in Milan. Tumor samples were profiled for fusion genes by fluorescent in situ hybridization (FISH) and for FUS/CHOP or EWS/CHOP mRNA transcripts by RT-PCR as already described. 48 Trabectedin (1.1 mg/kg, 24 h infusion) was used as front-line therapy. The biopsy was obtained before and 24 h after the first cycle.
